Comparison of the effects of carvedilol, propranolol, and verapamil on in vitro platelet function in healthy volunteers

Journal of Cardiovascular Pharmacology

Volumn 18, Issue , 1991, Pages S29-S34

  Gasser, J A ^a   Betterridge, D J ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b Rayne Institute ^*  (United Kingdom)

Author keywords

ADP; Carvedilol; Collagen; Epinephrine; Platelet aggregation; Propranolol; Verapamil

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; CARVEDILOL; COLLAGEN; CYCLIC AMP; PROPRANOLOL; THROMBOXANE B2; VERAPAMIL;

ATHEROSCLEROSIS; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; THROMBOCYTE AGGREGATION; VOLUNTEER;

ADRENERGIC BETA-ANTAGONISTS; BLOOD PLATELETS; CARBAZOLES; COMPARATIVE STUDY; CORONARY DISEASE; CYCLIC AMP; HUMAN; IN VITRO; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROPANOLAMINES; PROPRANOLOL; THROMBOXANE B2; VASODILATOR AGENTS; VERAPAMIL;

EID: 0025719978     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/00005344-199118041-00007     Document Type: Article

References (32)

1. Ross R, Glomset JA. The pathogenesis of atherosclerosis (second of two parts). N Engl J Med 1976;295:420-5.
2. Sixma JJ. GBRBloom AL, Thomas DP, eds. Haemostasis and thrombosis Edinburgh: Churchhill-Livingstone, 1981:252-67.
3. Brodde OE, Stuka N, Demuth V, et al. Alpha- and beta-adrenoreceptors in circulating blood cells of essential hypertensive patients: Increased receptor density and responsiveness. Clin Exp Hypertens 1985;7:1135-50.
4. McMahon SW, Cutler JA. Furberg CD. Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: A review of randomized controlled trials. Prog Cardiovasc Dis 1986;29(suppl 11:99-118.
5. Frishman WH, Weksler B, Christodoulou JP, Smithen C, Killip T. Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol. Circulation 1974;50:887-96.
6. Weksler BB, Gillick M, Pink J. Effect of propranolol on platelet function. Blood 1977:49:185-96.
7. Kerry R, Scrutton MC. Wallis RB. Beta-adrenoceptor antagonists and human platelets. Relationship of effects to lipid solubility. Biochem Pharmacol 1984;33:2615-22.
8. Ring ME, Corrigan JJ, Fenster PE. Antiplatelet effects of oral diltiazem, propranolol and their combination [Abstract]. Clin Res 1987;35:116.
9. Dale J, Landmark KH, Myhre E. The effects of nifedipine, a calcium antagonist, on platelet function. Am Heart J 1983;105:103-5.
10. Jones CR. Pasanisi F, Elliott HL. Reid JL. Effects of verapamil and nisoldipine on human platelets. In vivo and in vitro studies. Br J Clin Pharmacol 1985:20:191-6.
11. Addonizio VP. Fisher CA. Strauss JF, Edmunds LH. Inhibition of human platelet function by verapamil. Thromb Res 1982:28:545-56.
12. Addonzio VP, Fisher CA, Strauss JF, Wachtfogel YT, Col-man RW, Josephson ME. Effects of verapamil and diltiazem on human platelet function. Am J PIivsioI 1986:250:H366-71.
13. Johnson GJ. Leis LA, Francis GS. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha-2-adrenergic receptors and thromboxane A-2-induced aggregation of human platelets. Circulation 1986:73:847-54.
14. Someya N, Morotomi Y, Kodama K, et al. Suppressive effect of captopril on platelet aggregation in essential hypertension. J Cardiovasc Pharmacol 1984;6:840-3.
15. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol (Lond) 1963:168:178-95.
16. MacIntyre DE. Busfield M, Shaw AM. Regulation of platelet cytosolic free calcium by cyclic nucleotides and protein kinase C. FEBS Lett 1985:188:383-8.
17. Kannel WB, Gordon T. Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease: The Framingham Study. Am J Cardiol 1971;27:335-45.
18. Zusman RM. Alternatives to traditional antihypertensive therapy. AHA Focus Series. Hypertension 1987:1:14-9.
19. Paul O. The Medical Research Council Trial. AHA Focus Series. Hypertension 1987:1:20-3.
20. Zweifler AJ. Antihypertensive therapy: The unanswered question. Mod Med 1988:56:109-10.
21. Hansson L. What are we really achieving with long-term drug therapy? Am J Hypertens 1988;1:414-20.
22. Berglund G. Does antihypertensive treatment precipitate myocardial infarction? Acta Med Seand 1987;222:193-4.
23. Leren P. The hypertension-CHD dilemma. Acta MedScand 1985:217:145-7.
24. Doyle AE. Does hypertension predispose to coronary disease? Conflicting epidemiological and experimental evidence. Am J Hypertens 1988:1:319-24.
25. Leren P. Effects of antihypertensive drugs on lipid metabolism. Clin Ther 1987:9:326-32.
26. Houston MC. The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics. Am Heart J 1988:115:640-56.
27. Cornfield J. Joint dependence of risk of coronary heart disease on serum cholesterol and systolic blood pressure: A discriminant function analysis. Fed Proc 1962:21:58-61.
28. Hamet P. Tremblay J. Sugimoto H. Platelets in hypertension and peripheral vascular disease. GBRLongenecker GL, ed. The platelets: Physiology and pharmacology. New York: Academic Press. 1985:367-81.
29. DeClerck F. Blood platelets in human essential hypertension. Agents Actions 1986;18:563-80.
30. Nyrop M. Zweifler AJ. Platelet aggregation in hypertension and the effects of antihypertensive therapy. J Hvpertens 1988:6:263-9.
31. Turitto VT. Blood viscosity, mass transport, and thrombo-genesis. Prog Hemost Tliromb 1982:6:139-77.
32. Hamm CW. Lorenz RL, Bleifeld W, Kupper W, Wober W, Weber PC. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 1987:10:988-1004.